Ramiro Ribeiro - 03 Jan 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Medical Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
03 Jan 2025
Net transactions value
$0
Form type
4
Filing time
07 Jan 2025, 16:04:21 UTC
Previous filing
04 Mar 2024
Next filing
12 Nov 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +59,000 $0.000000 59,000 03 Jan 2025 Common Stock 59,000 $0.000000 Direct F1
transaction EYPT Stock Option (Right to Buy) Award $0 +117,000 $0.000000 117,000 03 Jan 2025 Common Stock 117,000 $8.26 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units will vest in three ratable annual installments beginning January 3, 2026.
F2 The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.